Leerink Partners Begins Coverage on Zoetis (NYSE:ZTS)

Analysts at Leerink Partners assumed coverage on shares of Zoetis (NYSE:ZTS) in a report issued on Monday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $215.00 price target on the stock. Leerink Partners’ price objective would suggest a potential upside of 21.51% from the company’s current price.

ZTS has been the topic of several other research reports. BTIG Research upped their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Stifel Nicolaus increased their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Piper Sandler lifted their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Eleven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $220.80.

Zoetis Trading Up 0.1 %

Zoetis stock opened at $176.94 on Monday. Zoetis has a 12 month low of $144.80 and a 12 month high of $201.92. The stock has a market cap of $79.83 billion, a price-to-earnings ratio of 33.26, a price-to-earnings-growth ratio of 2.71 and a beta of 0.89. The business has a 50 day moving average price of $183.16 and a two-hundred day moving average price of $181.01. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.36 EPS. As a group, equities analysts forecast that Zoetis will post 5.9 EPS for the current year.

Hedge Funds Weigh In On Zoetis

Hedge funds have recently modified their holdings of the stock. Peapack Gladstone Financial Corp raised its stake in Zoetis by 1.8% in the third quarter. Peapack Gladstone Financial Corp now owns 77,004 shares of the company’s stock valued at $15,045,000 after buying an additional 1,393 shares during the period. Tidal Investments LLC lifted its holdings in Zoetis by 3.4% during the 3rd quarter. Tidal Investments LLC now owns 15,210 shares of the company’s stock valued at $2,972,000 after purchasing an additional 500 shares during the last quarter. Destination Wealth Management boosted its position in Zoetis by 0.8% during the third quarter. Destination Wealth Management now owns 123,844 shares of the company’s stock worth $24,197,000 after purchasing an additional 1,027 shares during the period. Wilmington Savings Fund Society FSB increased its holdings in shares of Zoetis by 801.0% in the third quarter. Wilmington Savings Fund Society FSB now owns 18,606 shares of the company’s stock valued at $3,635,000 after purchasing an additional 16,541 shares during the last quarter. Finally, World Investment Advisors LLC raised its position in shares of Zoetis by 29.1% in the third quarter. World Investment Advisors LLC now owns 34,236 shares of the company’s stock valued at $6,689,000 after purchasing an additional 7,709 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.